StageZero Life Sciences (SZLS) Q3 2024 earnings summary

Executive summary

• Q3 2024 focused on revitalizing corporate offerings and integrating operational changes from Q2 and Q3 to drive uptake of the Aristotle test and increase revenues.

• Strategic review led to cost reductions, improved competitiveness, and operational realignment, including lab relocation and expanded clinical support in Europe and North America.

Financial highlights

• Q3 2024 revenue was $0.5M, down from $0.745M in Q3 2023; net loss narrowed to $0.399M from $0.822M year-over-year.

• Nine-month 2024 revenue was $1.412M, compared to $2.206M in the same period of 2023; net loss reduced to $1.435M from $3.035M year-over-year.

• Operating costs decreased by approximately 50% due to operational changes.

Outlook and guidance

• Revenue is expected to ramp up over the next twelve months as Aristotle testing scales and new partnerships are launched.

• Company anticipates paying auditors by December 31, 2024, and is seeking a partial revocation of the FFCTO to enable potential equity or debt funding.